SAN DIEGO – Radionetics Oncology officially has a suitor. The Torrey Pines-based biotech announced July 1 a strategic relationship with Eli Lilly and Company (NYSE: LLY) that gives the pharma giant exclusive rights to acquire Radionetics for $1 billion. The agreement also includes a $140 million upfront cash payment to Radionetics that will help fund […]
↧